Targeted Covalent Inhibitors for Drug Design
The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent interaction of a ligand with its biological target, a targeted covalent inhibitor (TCI) is designed such that the initial, reversible association is followed by the formation of a covalent bond between an electrophile on the ligand and a nucleophilic center in the protein. Although this approach offers a variety of potential benefits (high potency and extended duration of action), concerns over the possible toxicological consequences of protein haptenization have hindered the development of the TCI concept. Recently, approaches to mitigate the risk of serious adverse reactions to this new class of agent have emerged, thus stimulating interest in the field and leading to authorization of the first cadre of TCIs to be marketed. The covalent inhibitor approach is rapidly gaining acceptance as a valuable tool in drug discovery, and is poised to make a major impact on the design of enzyme inhibitors and receptor modulators.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the oxidation of drugs such as furosemide, isoniazid, acetaminophen, halothane, and model hepatotoxins via cytochrome P-450 can lead to hepatotoxic effects in animals and humans [131, 132].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [132]
Citations
Cites
The growing applications of click chemistry
Moses, J. E., & Moorhouse, A. D. (2007) · Chem. Soc. Rev. · doi:10.1039/b613014n · Cited by 2,367
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Self-citationCommon and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity
Guengerich, F. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002583 · Cited by 1,655
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Self-citationStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Self-citation
Research works printed but not linked: 7
- Parmar S., 2014, Pharm. Ther., 39, 483
- Johansson M. H., 2012, Mini-Rev. Med. Chem., 12, 1330
- Campuzano I. D. G., 2015, J. Biomol. Screening, 1
- Guerciolini R., 1997, Int. J. Obes., 21, 12
- Kumar S., 2008, Curr. Opin. Drug Discovery Dev., 11, 43
- Strelevitz T. J., 2015, Drug Metab. Rev., 47, 59
- The Wall Street Journal December 2 2015.
Cited by
Items 201–300 of 618
Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease
Liu, M., Xu, B., Ma, Y., Shang, L., Ye, S., & Wang, Y. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105102 · Cited by 24
Zhang, Z., Wang, Y., Chen, X., Song, X., Tu, Z., Chen, Y., Zhang, Z., & Ding, K. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116457 · Cited by 24
Zhang, Y., Zhu, G., Liu, W., Xiong, Y., Hu, Q., Zhuang, X., Jia, G., Zhang, W., & Ge, G. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154796 · Cited by 24
Aknine, N., Pelletier, R., & Klymchenko, A. S. (2025) · JACS Au · doi:10.1021/jacsau.4c01134 · Cited by 24
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update
Roskoski, R. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107805 · Cited by 23
Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease
Ngo, C., Fried, W., Aliyari, S. R., Feng, J. J., Qin, C., Zhang, S., Yang, H., Shanaa, J., Feng, P., Cheng, G., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00810 · Cited by 23
Bioactivation of herbal constituents: mechanisms and toxicological relevance
Wen, B., & Gorycki, P. D. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1655570 · Cited by 26
Molecular Interrogation to Crack the Case of O‐GlcNAc
Estevez, A., Zhu, D., Blankenship, C. M., & Jiang, J. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000155 · Cited by 23
Recent advances in the design of small molecular drugs with acrylamides covalent warheads
Liang, L., Zhang, Z., You, Q., & Guo, X. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117902 · Cited by 23
Hu, G., Zhou, Z., Tang, G., Liu, Y., Zhang, X., Huang, Y., Yan, G., Xiao, J., Yan, W., Li, J., et al. (2024) · Small · doi:10.1002/smll.202407480 · Cited by 22
Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
Tao, H., Yang, B., Farhangian, A., Xu, K., Li, T., Zhang, Z., & Li, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02760 · Cited by 22
An mRNA Display Approach for Covalent Targeting of a Staphylococcus aureus Virulence Factor
Wang, S., Woods, E. C., Jo, J., Zhu, J., Hansel-Harris, A., Holcomb, M., Llanos, M. A., Pedowitz, N. J., Upadhyay, T., Bennett, J. M., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c15713 · Cited by 22
Poirier, D., Roy, J., & Maltais, R. (2021) · Cancers · doi:10.3390/cancers13081841 · Cited by 24
Identification of Tubocapsanolide A as a novel NLRP3 inhibitor for potential treatment of colitis
Chen, C., Liu, X., Gong, L., Zhu, T., Zhou, W.-X., Kong, L., & Luo, J. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114645 · Cited by 22
Relative Nuclease Resistance of a DNA Aptamer Covalently Conjugated to a Target Protein
Tabuchi, Y., Yang, J., & Taki, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147778 · Cited by 22
Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1
Alboreggia, G., Udompholkul, P., Baggio, C., Muzzarelli, K. M., Assar, Z., & Pellecchia, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00277 · Cited by 22
Himmelbauer, M. K., Bajrami, B., Basile, R., Capacci, A. G., Chen, T., Choi, C. K., Gilfillan, R., de Turiso, F. G.-L., Gu, C., Hoemberger, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00220 · Cited by 22
Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53
Klett, T., Schwer, M., Ernst, L. N., Engelhardt, M. U., Jaag, S., Masberg, B., Knappe, C., Lämmerhofer, M., Gehringer, M., & Boeckler, F. M. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s466829 · Cited by 23
Auf Lysin zielende, kovalente Inhibitoren
Pettinger, J., Jones, K., & Cheeseman, M. D. (2017) · Angewandte Chemie · doi:10.1002/ange.201707630 · Cited by 22
Khan, S., Bjij, I., Olotu, F. A., Agoni, C., Adeniji, E. A., & Soliman, M. E. S. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0304 · Cited by 23
Zhang, P., Min, Z., Gao, Y., Bian, J., Lin, X., He, J., Ye, D., Li, Y., Peng, C., Cheng, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02254 · Cited by 22
Petri, L., Ábrányi‐Balogh, P., Vagrys, D., Imre, T., Varró, N., Mándity, I. M., Rácz, A., Wittner, L., Tóth, K., Tóth, E. Z., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114163 · Cited by 22
Photogeneration of Quinone Methides as Latent Electrophiles for Lysine Targeting
Pérez–Ruíz, R., Molins‐Molina, O., Lence, E., González‐Bello, C., Miranda, M. A., & Jiménez, M. C. (2018) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.8b01559 · Cited by 22
Site-Specific Albumin-Selective Ligation to Human Serum Albumin under Physiological Conditions
Yu, X., Ruan, M., Wang, Y., Nguyen, A. D., Xiao, W., Ajena, Y., Solano, L. N., Liu, R., & Lam, K. S. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00361 · Cited by 22
Covalent Targeting of Histidine Residues with Aryl Fluorosulfates: Application to Mcl-1 BH3 Mimetics
Alboreggia, G., Udompholkul, P., Atienza, E. L., Muzzarelli, K. M., Assar, Z., & Pellecchia, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01541 · Cited by 21
Yuan, B., Feng, Y., Ma, M., Duan, W., Wu, Y., Liu, J., Zhao, H., Yang, Z., Zhang, S., & Xin, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01284 · Cited by 21
Fritz, R. A., Alzate‐Morales, J. H., SPENCER, J. M., Mulholland, A. J., & van der Kamp, M. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00480 · Cited by 21
Rioux, N., Smith, S. A., Korpal, M., O'Shea, M. B., Prajapati, S., Zheng, G. Z., Warmuth, M., & Smith, P. G. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3716-3 · Cited by 21
Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping
Wang, Y., Chen, Z., Dai, M., Sun, P., Wang, C., Gao, Y., Zhao, H., Zeng, W., Shen, L., Mao, W., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.014 · Cited by 21
Inhibition ofO-acetylserine sulfhydrylase by fluoroalanine derivatives
Franko, N., Grammatoglou, K., Campanini, B., Costantino, G., Jirgensons, A., & Mozzarelli, A. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1504040 · Cited by 21
A renaissance in targeting the PI3K/AKT/mTOR pathway
Conduit, S. E., Vasan, N., Brown, J. R., Perry, M. W. D., & Vanhaesebroeck, B. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01388-5 · Cited by 20
Zhang, B., Zhu, C., Chan, A. S. C., & Lu, G. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115457 · Cited by 20
Blackner, J. J., Schneider, O. M., Wong, W. O., & Hall, D. G. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c06360 · Cited by 20
Advancements, challenges, and future frontiers in covalent inhibitors and covalent drugs: A review
Hameed, M. S., Cao, H., Guo, L., Zeng, L., & Ren, Y. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100217 · Cited by 32
Jung, Y., Noda, N., Takaya, J., Abo, M., Toh, K., Tajiri, K., Cui, C., Zhou, L., Sato, S., & Uesugi, M. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00824 · Cited by 20
Design and Discovery of Covalent α-GalCer Derivatives as Potent CD1d Ligands
Kishi, J., Inuki, S., Kashiwabara, E., Suzuki, T., Dohmae, N., & Fujimoto, Y. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.9b00700 · Cited by 20
Slow-Binding and Covalent HDAC Inhibition: A New Paradigm?
Raouf, Y. S., & Moreno–Yruela, C. (2024) · JACS Au · doi:10.1021/jacsau.4c00828 · Cited by 21
Exploring the landscape of post-translational modification in drug discovery
Cao, Y., Yu, T., Zhu, Z., Zhang, Y., Sun, S., Li, N., Gu, C., & Yang, Y. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108749 · Cited by 21
Covalent inhibition of ACSL4 alleviates ferroptosis-induced acute liver injury
Linghu, M., Luo, X., Zhou, X., Liu, D., Huang, Q. W., Ru, Y., Luo, Y., Ma, Y., & Huang, Y. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.06.004 · Cited by 20
Discovery of Covalent Ligands with AlphaFold3
Shamir, Y., Gabizon, R., Rogel, A., Lin, D. Y.-W., Andreotti, A. H., & London, N. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c22222 · Cited by 22
Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery
Zhao, Z., & Bourne, P. E. (2022) · Pharmaceuticals · doi:10.3390/ph15111322 · Cited by 19
The discovery of novel imidazo[1,2- a ]pyridine derivatives as covalent anticancer agents
Song, Q., Zhang, Q., Fan, X., Kayaat, F., Lv, R., Li, J., & Wang, Y. (2024) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob00694a · Cited by 19
New techniques and strategies in drug discovery (2020–2024 update)
Gong, Q., Song, J. H., Song, Y., Tang, K., Yang, P., Wang, X., Zhao, M., Ouyang, L., Rao, L., Yu, B., et al. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110456 · Cited by 19
Li, A., Li, S., Wang, P. G., Dang, C., Fan, X. M., Chen, M., Liu, D., Li, F., Liu, H., Zhang, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02939 · Cited by 19
Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors
Dai, J., Yang, L., & Addison, G. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666190617152011 · Cited by 19
Rational design of a DNA sequence-specific modular protein tag by tuning the alkylation kinetics
Nguyen, T. M., Nakata, E., Zhang, Z., Saimura, M., Dinh, H., & Morii, T. (2019) · Chemical Science · doi:10.1039/c9sc02990g · Cited by 19
A targeted covalent inhibitor of p97 with proteome-wide selectivity
Ye, Z., Wang, K., Chen, L., Jin, X., Chen, H., Tang, G., Yao, S. Q., Feng, Z., & Zhang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.003 · Cited by 19
Identification of the first structurally validated covalent ligands of the small GTPase RAB27A
Jamshidiha, M., Lanyon‐Hogg, T., Sutherell, C. L., Craven, G. B., Tersa, M., Vita, E. D., Brustur, D., Pérez‐Dorado, I., Hassan, S., Petracca, R., et al. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00225b · Cited by 19
Corso, A. D., Catalano, M., Schmid, A. S., Scheuermann, J., & Neri, D. (2018) · Angewandte Chemie · doi:10.1002/ange.201811650 · Cited by 19
Nie, W., Lu, Y., Pan, C., Gao, J., Luo, M., Du, J., Wang, J., Luo, P., Zhu, H., Che, J., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105673 · Cited by 18
Limitations of Ligand-Only Approaches for Predicting the Reactivity of Covalent Inhibitors
Voice, A. T., Tresadern, G., van Vlijmen, H., & Mulholland, A. J. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00404 · Cited by 18
Du, L., Yee, S. S., Karthik, R., & Risinger, A. L. (2020) · Nature Communications · doi:10.1038/s41467-019-14277-w · Cited by 18
Recent applications of covalent chemistries in protein–protein interaction inhibitors
Chan, A. M., Goodis, C. C., Pommier, E. G., & Fletcher, S. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00112h · Cited by 19
Maltais, R., Trottier, A., Roy, J., Ayan, D. P., Bertrand, N., & Poirier, D. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.12.007 · Cited by 20
Leung, C., Kenny, J. R., Hop, C. E. C. A., & Yan, Z. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.06.029 · Cited by 18
Inhibition of metabolic cooperation in Chinese hamster cells by organochlorine pesticides.
Kurata, M., Hirose, K., & Umeda, M. (1982) · PubMed · Cited by 22
Bhujbal, S. P., & Hah, J. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01566-w · Cited by 18
Shen, Z., Pu, M., Xie, Y., Junxing, L., Zhu, S., Wei, L., Zheng, W., Zhang, L., Wang, X., Zhang, C., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.170199 · Cited by 17
Raouf, Y. S., Sedighi, A., Geletu, M., Frere, G. A., Allan, R. G., Nawar, N., de Araujo, E. D., & Gunning, P. T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01236 · Cited by 17
Targeted degradation of Pin1 by protein-destabilizing compounds
Alboreggia, G., Udompholkul, P., Rodriguez, I., Blaha, G. M., & Pellecchia, M. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403330121 · Cited by 18
Fei, W.-L., Wang, Y., Feng, Q.-L., Li, C.-T., Jiang, R.-X., Zhang, S.-D., Pan, Y., Ni, P.-F., Huang, F.-R., Huangfu, Y.-B., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117183 · Cited by 17
Wang, Y., Zhang, Y., Liu, J., Zhao, J., Wang, C. W. C., Meng, F., Cai, X., Zhang, M., Aliper, A. M., Liang, T., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03205 · Cited by 17
Pearson, R. J., Blake, D., Mezna, M., Fischer, P. M., Westwood, N. J., & McInnes, C. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.06.001 · Cited by 17
Olotu, F. A., Adeniji, E. A., Agoni, C., Bjij, I., Khan, S., El-Rashedy, A. A. E., & Soliman, M. E. S. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1516035 · Cited by 17
Covalent inhibitor reactivity prediction by the electrophilicity index—in and out of scope
Hermann, M. R., Pautsch, A., Grundl, M. A., Weber, A., & Tautermann, C. S. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00342-w · Cited by 17
Banerjee, S. (2020) · Biophysical Chemistry · doi:10.1016/j.bpc.2020.106510 · Cited by 17
Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ
Fournier, J. C. L., Evans, J. P., Zappacosta, F., Thomas, D. A., Patel, V. K., White, G. V., Campos, S., & Tomkinson, N. C. O. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00225 · Cited by 19
Mutual leveraging of proximity effects and click chemistry in chemical biology
Dong, R., Yang, X., Wang, B., & Ji, X. (2022) · Medicinal Research Reviews · doi:10.1002/med.21927 · Cited by 18
Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation
Yu, W., Weber, D. J., & MacKerell, A. D. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00232 · Cited by 16
Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets
Lee, J., & Park, S. B. (2022) · Pharmaceuticals · doi:10.3390/ph15121478 · Cited by 17
Progress on the Pharmacological Targeting of Janus Pseudokinases
Henry, S. P., & Jorgensen, W. L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00926 · Cited by 16
Applications of genetic code expansion technology in eukaryotes
Guo, Q.-R., & Cao, Y. J. (2023) · Protein & Cell · doi:10.1093/procel/pwad051 · Cited by 17
Utsugi, Y., Kobuchi, H., Kawamura, Y., Atito, A. S. A., Nagao, M., Isoda, H., & Miyamae, Y. (2019) · Molecules · doi:10.3390/molecules24102019 · Cited by 16
Warheads for designing covalent inhibitors and chemical probes
Ábrányi‐Balogh, P., & Keserű, G. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821433-6.00007-6 · Cited by 19
Protein Modifications: From Chemoselective Probes to Novel Biocatalysts
Pessatti, T. B., Terenzi, H. F., & Bertoldo, J. B. (2021) · Catalysts · doi:10.3390/catal11121466 · Cited by 16
The Proteome‐Wide Potential for Reversible Covalency at Cysteine
Senkane, K., Vinogradova, E. V., Suciu, R. M., Crowley, V. M., Zaro, B. W., Bradshaw, J. M., Brameld, K. A., & Cravatt, B. F. (2019) · Angewandte Chemie · doi:10.1002/ange.201905829 · Cited by 16
Sulforaphane is a reversible covalent inhibitor of 3‐chymotrypsin‐like protease of SARS‐CoV‐2
Chen, Z., Du, R., Cooper, L. M., Achi, J. G., Dong, M., Ran, Y., Zhang, J., Zhan, P., Rong, L., & Cui, Q. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28609 · Cited by 16
Lagoutte, R., Pastor, M., Berthet, M., & Winssinger, N. (2018) · Tetrahedron · doi:10.1016/j.tet.2018.08.045 · Cited by 16
Sengupta, A., Wu, J., Seffernick, J. T., Sabag-Daigle, A., Thomsen, N., Chen, T., Capua, A. D., Bell, C. E., Ahmer, B. M. M., Lindert, S., et al. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.08.017 · Cited by 17
Structure-based design of covalent inhibitors targeting metallo-β-lactamases
Chen, C., & Yang, K. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112573 · Cited by 16
Chen, P., Sun, J., Zhu, C., Tang, G., Wang, W., Xu, M., Xiang, M., Zhang, C., Zhang, Z., Gao, L., et al. (2022) · Angewandte Chemie · doi:10.1002/ange.202203878 · Cited by 17
Structure-Aided Computational Design of Triazole-Based Targeted Covalent Inhibitors of Cruzipain
Cerutti, J. P., Diniz, L. A., Santos, V. C., Larrea, S. C. V., Alonso, G., Ferreira, R. S., Dehaen, W., & Quevedo, M. A. (2024) · Molecules · doi:10.3390/molecules29174224 · Cited by 15
Trottier, A., Maltais, R., Ayan, D. P., Barbeau, X., Roy, J., Perreault, M., Poulin, R., Lagüe, P., & Poirier, D. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.004 · Cited by 15
Li, P., Shi, B., Li, L., Yin, J., Yao, Q., Tian, Y., Huang, X., Ji, X., Xiao, C., Li, Q., et al. (2022) · Journal of Analysis and Testing · doi:10.1007/s41664-022-00240-0 · Cited by 15
Overview of Adductomics in Toxicology
Lockridge, O. (2023) · Current Protocols · doi:10.1002/cpz1.672 · Cited by 15
Synthesis of deoxyelephantopin analogues
Lagoutte, R., Serba, C., & Winssinger, N. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.132 · Cited by 15
Metabolic characterisation of transglutaminase 2 inhibitor effects in breast cancer cell lines
Gallo, M. L., Ferrari, E., Terrazzan, A., Brugnoli, F., Spisni, A., Taccioli, C., Aguiari, G., Trentini, A., Volinia, S., Keillor, J. W., et al. (2023) · FEBS Journal · doi:10.1111/febs.16931 · Cited by 14
Benetik, S. F., Knez, D., Obreza, A., Košak, U., & Gobec, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108748 · Cited by 15
Reimer, B. M., Awoonor‐Williams, E., Golosov, A. A., & Horn̆ák, V. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01281 · Cited by 16
Rapid Covalent Labeling of Membrane Proteins on Living Cells Using a Nanobody–Epitope Tag Pair
Cabalteja, C. C., Sachdev, S., & Cheloha, R. W. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00334 · Cited by 14
Dumas, A., Garsi, J.-B., Poissonnet, G., & Hanessian, S. (2020) · ACS Omega · doi:10.1021/acsomega.0c04181 · Cited by 14
Uematsu, S., Tabuchi, Y., Ito, Y., & Taki, M. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00301 · Cited by 14
Bonus, M., Greb, J., Majmudar, J. D., Boehm, M., Korczynska, M., Nazemi, A., Mathiowetz, A. M., & Gohlke, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169196 · Cited by 13
Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies
Damghani, T., Chitnis, S. P., Abidakun, O. A., Patel, K. B., Lin, K. S., Ouellette, E. A., Lantry, A. M., & Heppner, D. E. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01661 · Cited by 14
Guan, I. A., Williams, K., Pan, J., & Liu, X. (2021) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202100036 · Cited by 14
Discovery of cysteine-targeting covalent histone methyltransferase inhibitors
Zhao, Y., Jiang, B., Gu, Z., Chen, T., Yu, W. H., Liu, S., Liu, X., Chen, D., Li, F., & Chen, W. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115028 · Cited by 13
Tillmanns, J., Häge, S., Borst, E. M., Wardin, J., Eickhoff, J., Klebl, B., Wagner, S., Wangen, C., Hahn, F., Socher, E., et al. (2023) · Cells · doi:10.3390/cells12081162 · Cited by 13
Precious Cargo: The Role of Polymeric Nanoparticles in the Delivery of Covalent Drugs
Weissberger, D., Stenzel, M. H., & Hunter, L. (2024) · Molecules · doi:10.3390/molecules29204949 · Cited by 12
Wu, L., Xu, S., Zhou, Y., Shi, D., Wang, M., Kim, M., & Zhan, P. (2025) · Science China Chemistry · doi:10.1007/s11426-025-2658-0 · Cited by 12
Small molecule inhibitors of anthrax edema factor
Jiao, G., Kim, S., Moayeri, M., Thai, A., Cregar, L., McKasson, L., O'Malley, S. W., Leppla, S. H., & Johnson, A. T. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.11.040 · Cited by 12
Metadata
- Authors
- Baillie, T. A.
- Affiliations
- University of Washington (US)
- Corresponding author
- Baillie, Thomas A.
- ORCID
- Baillie, Thomas A.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2016-08-19
- Volume
- 55
- Issue
- 43
- Pages
- 13408-13421
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2517550655
- Cited by
- 578
- References
- 118
- Citations by year
- 2026: 55 · 2025: 77 · 2024: 66 · 2023: 46 · 2022: 49 · 2021: 76 · 2020: 72 · 2019: 52 · 2018: 46 · 2017: 31 · 2016: 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- targeted covalent inhibitors, covalent drug design, drug toxicity, enzyme inhibitors, receptor modulators, drug discovery, non-covalent binding
- MeSH terms
- Animals, Enzyme Inhibitors, Humans, Ligands, Protein Kinases, Drug Design, Molecular Structure, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.